Connect Biopharma reports positive Phase 2 asthma, COPD data for rademikibart
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
Connect Biopharma Holdings Limited reported financial results for the third quarter and first nine months of 2026 on November 16, 2026, alongside updated detail on its Phase 2 Seabreeze STAT studies of rademikibart. The company reported preliminary topline data in September 2026 from the Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations, and said the results support advancement into Phase 3 development.1 Connect plans to meet with the FDA to seek alignment on potential Phase 3 registrational programs for asthma in December 2026 and for COPD in the first quarter of 2027.1
In the asthma study (CBP-201-206), patients receiving rademikibart achieved a 250 mL increase in post-bronchodilator FEV1 at Day 7, versus 120 mL with placebo (p=0.023), an effect maintained through Week 4 (p=0.012).1 The drug reduced the treatment failure rate by approximately 66% over 28 days compared with placebo (p=0.153), a result that missed statistical significance because the overall treatment failure rate was lower than projected.1 Using the entry criteria planned for a possible Phase 3 program, the observed reduction in treatment failure rate under a proposed baseline FEV1 cutoff of under 80% predicted was 86% (p=0.0282).1
In the COPD study (CBP-201-207), rademikibart showed an 81% reduction in treatment failure (p=0.0122) and an 85% reduction in new moderate-to-severe exacerbations (p=0.0301) through Week 4 versus placebo.1 Emergency department visits and hospital admissions for new exacerbations fell by 100% through Week 4 versus placebo (p=0.0137).1 The company said rademikibart was well tolerated in both studies, with no new safety signals and fewer treatment-emergent and serious adverse events than placebo.1
Financially, cash, cash equivalents and short-term investments totaled $19.5 million as of September 30, 2026.1 Net loss for the quarter was $16.2 million, or $0.26 per share, compared with $17.2 million, or $0.31 per share, a year earlier.1 Separately, Nasdaq notified Connect on November 12, 2026 that its shares had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, giving the company until May 11, 2027 to regain compliance.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.